| Ytd | 0.26% | |
| 1y | 5.52% |
| Open | 3.98 | Prev Close | 4.01 | Low | 3.81 | High | 4.00 | Mkt Cap | 396.83M |
| Vol | 1.06M | Avg Vol | 1.95M | EPS | -2.01 | P/E | N/A | Forward P/E | -2.57 |
| Beta | 0.71 | Short Ratio | 5.19 | Inst. Own | 106.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 3.88 | 200-d Avg | 3.92 | 1yr Est | 20.41 |
Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have earned a consensus recomm
Dimensional Fund Advisors LP lifted its position in shares of Larimar Therapeutics, Inc. (NASDAQ: LR
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lo
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the ana
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LR
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investo
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) wit
NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowe
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp i
Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigat
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ
FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes
BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LR
BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LR
JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Ov
Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lo
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the ana
Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and cl
BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: L
Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have been assigned a consensus
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and ra
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the a
* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 mill
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options t
Tom Yeung here with your Sunday Digest . In 2015, I visited the observatory at One World Trade Cent
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and ra
Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology compan
Larimar Therapeutics Inc (NASDAQ:LRMR) shares are soaring on Wednesday after multiple analysts reite
Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and r
Wedbush analyst Laura Chico reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and m
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company